Grace Therapeutics Inc (GRCE) Stock Price, Quote & News

Company Profile

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgi...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 322 1602

Website: www.gracetx.com

Address:

103 Carnegie Center, Suite 300, Princeton, United States

BB_88_ Mar. 20 at 9:03 PM

$GRCE can’t bring her down even in this market

0 · Reply

CharlieeMungerTWITS Mar. 20 at 8:46 PM

$GRCE

0 · Reply

JujuInvestor2013 Mar. 20 at 7:38 PM

$GRCE looking good grace 😊🙏🚀 that would be so great to go to 6-7$ before approval then it may fly to 15-18$ or even more 🫶

0 · Reply

basssque Mar. 20 at 7:24 PM

$GRCE Added, best overall performer in my entire portfolio and hold up strong AF in a weak market 💪💰

0 · Reply

BOUDIN420 Mar. 20 at 5:21 PM

$GRCE same here. Tiny float getting locked up imo

0 · Reply

janed102 Mar. 20 at 3:18 PM

$GRCE 15 Cent difference between buy and sell.. anyone showing anything different ?

1 · Reply

P0lish Mar. 20 at 2:37 PM

$GRCE 🚨 NEWS TODAY: Grace issued a PR — GTx-104 accepted at 2 medical conferences this week: • SCCM Critical Care Congress (Chicago, Mar 22–24) • AANN Annual Meeting (Dallas, Mar 21–24) • Phase 3 STRIVE-ON data: 19% reduction in hypotension vs oral nimodipine ✅ This is normal IR activity, not a black box violation. Positive pre-PDUFA scientific momentum — presenting in front of future prescribers. Black Box Day 4: CLEAN. Thesis intact. HOLD. Next trigger $5.50.

0 · Reply

BB_88_ Mar. 20 at 2:28 PM

$TNXP $GRCE let’s go

0 · Reply

PatienceisGrace Mar. 19 at 9:55 PM

$GRCE Data looks good, however anyone concerned about CMC issues? How is their manufacturing looking? I’ve seen a lot of solid bio plays with good data but they get a CRL due to CMC crap…

1 · Reply

basssque Mar. 19 at 9:17 PM

$GRCE announced today that abstracts have been accepted for presentation at two major medical conferences in March 2026 — an industry education workshop at the Society of Critical Care Medicine’s Critical Care Congress (March 22-24, Chicago) titled “Unmet Needs in aSAH: Limitations of Current Treatments” . This is a pre-commercial awareness play just 35 days before the PDUFA date.

0 · Reply

Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences

Feb 25, 2026, 8:00 AM EST - 24 days ago

Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 12, 2026, 8:00 AM EST - 5 weeks ago

Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update

Nov 17, 2025, 8:00 AM EST - 4 months ago

Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference

Nov 13, 2025, 8:00 AM EST - 4 months ago

Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update

Nov 11, 2025, 8:30 AM EST - 4 months ago

Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting

Oct 23, 2025, 8:00 AM EDT - 5 months ago

Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review

Sep 22, 2025, 8:00 AM EDT - 6 months ago

Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting

Sep 18, 2025, 8:30 AM EDT - 6 months ago

Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104

Sep 4, 2025, 8:00 AM EDT - 7 months ago

Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 8:00 AM EDT - 7 months ago

Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104

Aug 12, 2025, 8:00 AM EDT - 7 months ago

Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update

Jun 25, 2025, 8:00 AM EDT - 9 months ago

Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104

Jun 23, 2025, 8:00 AM EDT - 9 months ago

Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update

Jun 13, 2025, 8:00 AM EDT - 10 months ago

Grace Therapeutics to Participate in the 2025 BIO International Conference

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

MTNB

Feb 25, 2025, 8:00 AM EST - 1 year ago

Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 13, 2025, 8:00 AM EST - 1 year ago

Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update

Feb 10, 2025, 12:05 PM EST - 1 year ago

Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study

Feb 10, 2025, 8:05 AM EST - 1 year ago

Grace Therapeutics Announces Private Placement Financing of up to $30 Million

Feb 10, 2025, 8:01 AM EST - 1 year ago

Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

Jan 7, 2025, 8:00 AM EST - 1 year ago

Grace Therapeutics to Participate in Upcoming Investor Events January 2025

Oct 25, 2024, 8:00 AM EDT - 1 year ago

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

Sep 25, 2024, 7:30 AM EDT - 1 year ago

Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

Sep 5, 2024, 10:35 AM EDT - 1 year ago

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update

Jun 27, 2024, 4:05 PM EDT - 1 year ago

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Acasti Announces Year-End 2024 Financial Results, Provides Business Update

May 28, 2024, 4:05 PM EDT - 1 year ago

Acasti Pharma to Attend BIO International Convention 2024

Feb 12, 2024, 8:00 AM EST - 2 years ago

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

Feb 1, 2024, 8:00 AM EST - 2 years ago

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

Dec 13, 2023, 8:00 AM EST - 2 years ago

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

Nov 13, 2023, 8:00 AM EST - 2 years ago

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

Oct 4, 2023, 8:00 AM EDT - 2 years ago

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Acasti Announces $7.5 Million Private Placement Equity Financing

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Acasti to Participate in the H.C. Wainwright Global Investment Conference

Aug 11, 2023, 7:00 AM EDT - 2 years ago

Acasti Announces First Quarter 2024 Financial Results and Business Highlights

Aug 9, 2023, 4:05 PM EDT - 2 years ago

Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting

Jul 10, 2023, 9:00 AM EDT - 2 years ago

Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients

Jul 7, 2023, 8:00 AM EDT - 2 years ago

Acasti Pharma Announces 1-for-6 Reverse Stock Split

Jul 5, 2023, 9:00 AM EDT - 2 years ago

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

Jun 23, 2023, 7:00 AM EDT - 2 years ago

Acasti Pharma Reports Fiscal Year 2023 Operational Results

Jun 22, 2023, 9:00 AM EDT - 2 years ago

Acasti Announces Appointment of New Scientific Advisory Board Members

May 17, 2023, 9:00 AM EDT - 3 years ago

Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference

May 8, 2023, 7:00 AM EDT - 3 years ago

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

Apr 4, 2023, 8:01 AM EDT - 3 years ago

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND

Apr 4, 2023, 8:00 AM EDT - 3 years ago

Acasti Announces Appointment of Prashant Kohli as CEO

Mar 30, 2023, 8:30 AM EDT - 3 years ago

Acasti Pharma Inc. Announces the Resignation of a Director

BB_88_ Mar. 20 at 9:03 PM

$GRCE can’t bring her down even in this market

0 · Reply

CharlieeMungerTWITS Mar. 20 at 8:46 PM

$GRCE

0 · Reply

JujuInvestor2013 Mar. 20 at 7:38 PM

$GRCE looking good grace 😊🙏🚀 that would be so great to go to 6-7$ before approval then it may fly to 15-18$ or even more 🫶

0 · Reply

basssque Mar. 20 at 7:24 PM

$GRCE Added, best overall performer in my entire portfolio and hold up strong AF in a weak market 💪💰

0 · Reply

BOUDIN420 Mar. 20 at 5:21 PM

$GRCE same here. Tiny float getting locked up imo

0 · Reply

janed102 Mar. 20 at 3:18 PM

$GRCE 15 Cent difference between buy and sell.. anyone showing anything different ?

1 · Reply

P0lish Mar. 20 at 2:37 PM

0 · Reply

BB_88_ Mar. 20 at 2:28 PM

$TNXP $GRCE let’s go

0 · Reply

PatienceisGrace Mar. 19 at 9:55 PM

$GRCE Data looks good, however anyone concerned about CMC issues? How is their manufacturing looking? I’ve seen a lot of solid bio plays with good data but they get a CRL due to CMC crap…

1 · Reply

basssque Mar. 19 at 9:17 PM

0 · Reply

basssque Mar. 19 at 8:10 PM

$CING $RCKT $GRCE $AQST 1.💰2.💰3.💰4.💰

2 · Reply

CharlieeMungerTWITS Mar. 19 at 5:35 PM

$RCKT $GRCE you two girls competing for me?

1 · Reply

BB_88_ Mar. 18 at 8:33 PM

$GRCE she did well considering market conditions

0 · Reply

BB_88_ Mar. 18 at 12:31 AM

$GRCE gots to get over 5 before PDUFA - let’s go!

0 · Reply

Bogwood Mar. 17 at 5:31 PM

Ideally looking to parlay $GRCE and $ABVX by 3Q. I think $ABVX gets purchased before the maintainence readout, and $GRCE is a layup as evidenced by recent action

0 · Reply

CharlieeMungerTWITS Mar. 17 at 12:33 PM

$GRCE there shall be violent moves here soon

4 · Reply

Thorthegod Mar. 17 at 10:27 AM

$GRCE playing this one for good

0 · Reply

CharlieeMungerTWITS Mar. 16 at 9:43 PM

$GRCE violent moves babyyyy

0 · Reply

Merlintrader Mar. 16 at 8:45 PM

$GRCE https://www.merlintrader.com/grace-therapeutics-aprl23-decision/

0 · Reply

Bellz22 Mar. 16 at 7:30 PM

$GRCE wtf going on

2 · Reply

BB_88_ Mar. 16 at 7:27 PM

$GRCE send it

0 · Reply

Thorthegod Mar. 16 at 4:46 PM

$GRCE dang, i bought it too early!

0 · Reply

Market Cap	68.40M
Revenue (ttm)	0.00
Net Income (ttm)	-9.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	490,000
Avg Vol	227,580
Day's Range	N/A - N/A
Shares Out	15.47M
Stochastic %K	63%
Beta	0.71
Analysts	Strong Sell
Price Target	$11.83